Online inquiry

IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14341MR)

This product GTTS-WQ14341MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ANGPT2&VEGFA gene. The antibody can be applied in Diabetic macular edema, Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens; Humanized
RefSeq NM_001118887.2; NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 285; 7422
UniProt ID O15123; P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14341MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ890MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-181
GTTS-WQ5119MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Campath-1H
GTTS-WQ14448MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ7456MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GBR-830
GTTS-WQ2768MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG162
GTTS-WQ7660MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GEN-1029
GTTS-WQ4626MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986016
GTTS-WQ10950MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MBG-453
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW